CLINICAL_TRIALS
trial_result
· 2017-07-05
Clinical Trial Update: A Study of IDN-6556 in Subjects With Liver Cirrhosis [Phase 2]
Summary
Phase 2 trial of emricasan (IDN-6556) in subjects with liver cirrhosis was completed and results were posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Conatus Pharmaceuticals Inc. | Conditions: Liver Cirrhosis, Hepatic Cirrhosis | Phase 2 | Status: COMPLETED | Results posted: 2017-07-05